Hepta Bio, Inc

Hepta Bio, Inc is a US-based biotech company specializing in innovative liquid biopsy solutions aimed at enhancing early diagnostics for metabolic dysfunction-related diseases. Founded in 2022 and headquartered in California City, US, Hepta Bio, Inc focuses on developing liquid biopsy technology for metabolic dysfunction-associated steatohepatitis (MASH). It has successfully completed its first funding round, raising USD 6. 7 mn in Seed funding from prominent investors such as Felicis Ventures and Illumina Ventures on November 5, 2025.

The company is led by a team with substantial expertise in healthcare and technology, though specific founder details were not provided. Hepta specializes in developing a next-generation liquid biopsy platform specifically for metabolic dysfunction-associated steatohepatitis (MASH), targeting a significant gap in early diagnostics for this prevalent chronic disease affecting over 20 million Americans. The core offering involves a non-invasive blood test that analyzes epigenetic patterns in cell-free DNA to reveal liver biology, thereby providing clinicians with critical tissue-level insights. This innovative diagnostic tool is designed for routine clinical practice, allowing for early detection, treatment decision-making, and longitudinal monitoring of liver inflammation and fibrosis.

Hepta's technology is particularly valuable for healthcare providers and clinicians across the United States, enabling them to identify at-risk patients more quickly and efficiently. As the platform evolves, Hepta aims to expand its applications to other serious chronic diseases that share similar biological underpinnings, broadening the impact of its diagnostic capabilities. Hepta's revenue model is primarily driven by its innovative liquid biopsy service, which is positioned as a diagnostic tool for healthcare providers. Transactions typically occur on a B2B basis, where clinical laboratories and healthcare institutions incorporate Hepta's blood-based testing services into their offerings to patients.

The pricing structure is expected to reflect the advanced technology and insights provided, with healthcare providers paying for each test conducted, which can be integrated into standard patient care workflows. The product is designed to ensure accessibility and efficiency in diagnosing metabolic diseases, thereby facilitating earlier interventions. Hepta's flagship service, focusing on MASH diagnostics, aims to create a sustainable revenue stream by addressing a critical need in chronic disease management and harnessing partnerships with healthcare providers to enhance patient care outcomes. In November 2025, Hepta Bio, Inc raised USD 6.

7 mn in Seed funding co-led by new investors Felicis Ventures and Illumina Ventures, with participation from other new investors SeaX Ventures, Alumni Ventures, and AME Cloud Ventures. The company plans to utilize this funding to expand datasets, advance regulatory pathways, initiate commercialization, and present new clinical findings for liquid biopsy-based AI diagnostics in chronic liver disease. Hepta aims to design and launch new products targeting additional chronic diseases by 2026, while also looking to expand into international markets, particularly in Europe and Asia, in the next few years.